Sphere Medical achieves CE marking for Proxima 4

~ Preparation for commercial launch in Europe well underway ~

Sphere Medical Holding plc (AIM: SPHR.L), an innovative point-of-care monitoring and diagnostic devices company, is today pleased to announce that all four components of its Proxima 4 device have received CE mark registration, enabling market launch in Europe.

Proxima 4 is the new generation of Sphere’s innovative patient-connected device used for measuring blood gases, electrolytes and metabolites. It incorporates a number of significant enhancements over the currently available product, Proxima 3. Based on market demand and usability studies, these include the addition of glucose and sodium to the panel of analytes, and a number of important usability improvements.

The Company is continuing with preparations for the European commercial launch of Proxima 4, including readying the supply chain, and it remains on track to achieve the launch later this year.

Wolfgang Rencken, the Company’s Chief Executive Officer, commented: “With the CE-marking of Proxima 4 we have achieved one of our strategic goals for 2016. This will mean that the benefits of Proxima will be available to a much larger group of patients. We now look forward to its commercial launch later this year and building sales momentum.”

Professor Mike Grocott, consultant in Critical Care Medicine at the University Hospital Southampton, commented: “The recent time and motion study we conducted at University Hospital Southampton clearly highlighted the workflow benefits of using Proxima on critically ill, unstable patients. We look forward to the launch of Proxima 4 and the opportunity to use this device on a larger patient group within the ICU.”